Memo Therapeutics

Memo Therapeutics AG is a clinical-stage biotechnology company developing best-in-class therapeutic antibodies derived from the immune systems of elite responders—patients who mount exceptionally potent natural immune responses to viruses or cancer. The company's proprietary DROPZYLLA® technology platform enables the high-fidelity mining of antibody repertoires to isolate highly potent candidates. With its lead asset, potravitug, in a pivotal Phase II trial for BK polyomavirus infection and a partnered oncology pipeline, Memo is positioned to address significant unmet needs in transplantation and oncology. The company operates as a private entity, leveraging strategic partnerships to advance its programs.

DROPZYLLA® - A proprietary antibody repertoire copying engine that enables high-fidelity identification and isolation of potent antibodies from the immune cells of elite responder patients (e.g., to viruses or cancer).

In BKV infection, Memo's potravitug is a first-mover in late-stage clinical development, facing competition from other biotechs with earlier-stage antibodies and antiviral strategies. In oncology, the competitive landscape is intense, but Memo's elite responder discovery approach could yield differentiated, first-in-class assets against novel targets.